Immunosurveillance  	Immunosurveillance  	 NNP	B-NP
and  	and  	 CC	O
immunoediting--can  	immunoediting--can  	 JJ	B-NP
the  	the  	 DT	O
immune  	immune  	 JJ	O
response  	response  	 NN	O
be  	be  	 VB	O
made  	made  	 VBN	O
more  	more  	 JJR	O
immunodemocratic 	immunodemocratic 	 NN	B-NP
?  	?  	 .	O
Increasing  	Increasing  	 VBG	B-NP
evidence  	evidence  	 NN	I-NP
has  	has  	 VBZ	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
immune  	immune  	 JJ	O
system  	system  	 NN	O
is  	is  	 VBZ	O
able  	able  	 JJ	O
to  	to  	 TO	O
mount  	mount  	 VB	O
responses  	responses  	 NNS	O
against  	against  	 IN	O
tumors  	tumors  	 NNS	O
and  	and  	 CC	O
that  	that  	 IN	O
these  	these  	 DT	O
responses  	responses  	 NNS	O
can  	can  	 MD	O
be  	be  	 VB	O
enhanced  	enhanced  	 VBN	O
using  	using  	 VBG	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
strategies 	strategies 	 NNS	O
.  	.  	 .	O
Several  	Several  	 JJ	O
of  	of  	 IN	O
these  	these  	 DT	O
strategies  	strategies  	 NNS	O
are  	are  	 VBP	O
currently  	currently  	 RB	O
being  	being  	 VBG	O
evaluated  	evaluated  	 VBN	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
trials 	trials 	 NNS	I-NP
,  	,  	 ,	O
where  	where  	 WRB	O
their  	their  	 PRP$	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
cost  	cost  	 NN	B-NP
effectiveness  	effectiveness  	 NN	I-NP
will  	will  	 MD	O
be  	be  	 VB	O
ascertained 	ascertained 	 NNS	O
.  	.  	 .	O
Sadly 	Sadly 	 RB	O
,  	,  	 ,	O
we  	we  	 PRP	O
have  	have  	 VBP	O
to  	to  	 TO	O
admit  	admit  	 VB	O
that  	that  	 IN	O
despite  	despite  	 IN	O
great  	great  	 JJ	O
expectations  	expectations  	 NNS	B-NP
and  	and  	 CC	O
enormous  	enormous  	 JJ	O
achievements  	achievements  	 NNS	B-NP
in  	in  	 IN	O
basic  	basic  	 JJ	O
immunology  	immunology  	 NN	B-NP
and  	and  	 CC	O
molecular  	molecular  	 JJ	B-NP
biology 	biology 	 NN	I-NP
,  	,  	 ,	O
immunotherapeutic  	immunotherapeutic  	 JJ	B-NP
interventions  	interventions  	 NNS	I-NP
relying  	relying  	 VBG	O
on  	on  	 IN	O
the  	the  	 DT	O
elicitation  	elicitation  	 NN	O
of  	of  	 IN	O
cytotoxic  	cytotoxic  	 JJ	B-NP
cellular  	cellular  	 JJ	I-NP
immunity  	immunity  	 NN	I-NP
so  	so  	 RB	O
far  	far  	 RB	O
have  	have  	 VBP	O
had  	had  	 VBN	O
limited  	limited  	 JJ	O
success 	success 	 NN	O
.  	.  	 .	O
We  	We  	 PRP	O
have  	have  	 VBP	O
found  	found  	 VBN	O
that  	that  	 IN	O
gene-based  	gene-based  	 JJ	B-NP
vaccination  	vaccination  	 NN	I-NP
is  	is  	 VBZ	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
breaking  	breaking  	 VBG	B-NP
tolerance  	tolerance  	 NN	I-NP
to  	to  	 TO	O
tumor-associated  	tumor-associated  	 JJ	O
antigens 	antigens 	 NN	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
the  	the  	 DT	O
response  	response  	 NN	O
is  	is  	 VBZ	O
directed  	directed  	 VBN	O
towards  	towards  	 IN	O
few  	few  	 JJ	O
of  	of  	 IN	O
the  	the  	 DT	O
potential  	potential  	 JJ	B-NP
epitopes  	epitopes  	 JJ	I-NP
due  	due  	 JJ	O
to  	to  	 TO	O
immunodominance 	immunodominance 	 VB	O
.  	.  	 .	O
Tumor  	Tumor  	 NN	B-NP
cells  	cells  	 NNS	I-NP
that  	that  	 WDT	O
have  	have  	 VBP	O
lost  	lost  	 VBN	O
the  	the  	 DT	O
immunodominant  	immunodominant  	 JJ	B-NP
epitope  	epitope  	 JJ	I-NP
due  	due  	 JJ	O
to  	to  	 TO	O
mutations  	mutations  	 NNS	O
would  	would  	 MD	O
no  	no  	 RB	O
longer  	longer  	 RB	O
be  	be  	 VB	O
recognized  	recognized  	 VBN	O
and  	and  	 CC	O
would  	would  	 MD	O
evade  	evade  	 VB	O
immune  	immune  	 JJ	O
surveillance 	surveillance 	 NN	B-NP
.  	.  	 .	O
Designing  	Designing  	 VBG	O
a  	a  	 DT	O
protocol  	protocol  	 NN	O
for  	for  	 IN	O
immunotherapy 	immunotherapy 	 NN	B-NP
,  	,  	 ,	O
therefore 	therefore 	 RB	O
,  	,  	 ,	O
necessitates  	necessitates  	 JJ	O
stimulation  	stimulation  	 NN	O
of  	of  	 IN	O
an  	an  	 DT	O
immune  	immune  	 JJ	O
response  	response  	 NN	O
directed  	directed  	 VBN	O
against  	against  	 IN	O
a  	a  	 DT	O
multitude  	multitude  	 NN	O
of  	of  	 IN	O
epitopes 	epitopes 	 NN	B-NP
.  	.  	 .	O
Increasing  	Increasing  	 VBG	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
epitopes  	epitopes  	 JJ	B-NP
available  	available  	 JJ	I-NP
for  	for  	 IN	I-NP
presentation  	presentation  	 NN	I-NP
to  	to  	 TO	O
T  	T  	 NN	B-NP
cells  	cells  	 NNS	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
initial  	initial  	 JJ	O
step 	step 	 NN	O
.  	.  	 .	O
It  	It  	 PRP	O
mandates  	mandates  	 VBZ	O
increased  	increased  	 VBN	B-NP
degradation  	degradation  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
antigen  	antigen  	 NN	I-NP
following  	following  	 VBG	O
DNA  	DNA  	 NN	B-NP
immunization 	immunization 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
logical  	logical  	 JJ	B-NP
continuation  	continuation  	 NN	I-NP
involves  	involves  	 VBZ	O
manipulation  	manipulation  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
intimate  	intimate  	 JJ	O
mechanisms  	mechanisms  	 NNS	O
controlling  	controlling  	 VBG	O
the  	the  	 DT	O
processes  	processes  	 NNS	O
of  	of  	 IN	O
stimulation  	stimulation  	 NN	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
suppression  	suppression  	 NN	O
of  	of  	 IN	O
T  	T  	 NN	B-NP
cells  	cells  	 NNS	I-NP
recognizing  	recognizing  	 VBG	O
the  	the  	 DT	O
sub-dominant  	sub-dominant  	 JJ	O
epitopes  	epitopes  	 NNS	B-NP
thus  	thus  	 RB	O
offering  	offering  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
immunologist  	immunologist  	 JJ	B-NP
ways  	ways  	 NNS	I-NP
for  	for  	 IN	O
overcoming  	overcoming  	 JJ	O
tumor-immune  	tumor-immune  	 JJ	O
evasion  	evasion  	 NN	B-NP
strategies 	strategies 	 NNS	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
now  	now  	 RB	O
have  	have  	 VB	O
the  	the  	 DT	O
necessary  	necessary  	 JJ	O
instruments  	instruments  	 NNS	O
to  	to  	 TO	O
ask  	ask  	 VB	O
all  	all  	 PDT	O
the  	the  	 DT	O
fundamental  	fundamental  	 JJ	B-NP
questions  	questions  	 NNS	I-NP
of  	of  	 IN	I-NP
tumor  	tumor  	 NN	I-NP
immunology 	immunology 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
better  	better  	 JJR	O
understanding  	understanding  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
immune  	immune  	 JJ	O
escape  	escape  	 NN	B-NP
mechanisms  	mechanisms  	 NNS	I-NP
and  	and  	 CC	O
those  	those  	 DT	O
underlying  	underlying  	 JJ	O
tumor-induced  	tumor-induced  	 JJ	O
immune  	immune  	 JJ	O
suppression  	suppression  	 NN	O
will  	will  	 MD	O
help  	help  	 VB	O
in  	in  	 IN	O
designing  	designing  	 VBG	O
novel  	novel  	 NN	O
and  	and  	 CC	O
more  	more  	 RBR	O
efficient  	efficient  	 JJ	O
protocols  	protocols  	 NNS	O
for  	for  	 IN	O
immunotherapy  	immunotherapy  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
setting 	setting 	 NN	I-NP
.  	.  	 .	O
